摘要
目的:对比分析含奈达铂联合化疗方案和含顺铂联合化疗方案治疗中晚期非小细胞肺癌的疗效和不良反应。方法:70例中晚期非小细胞肺癌患者,其中奈达铂治疗组(A组)34例,顺铂治疗组(B组)36例。结果:A组有效率(32.35%)和B组有效率(34.28%)无显著差异(P>0.05);A组胃肠道反应(23.53%)发生率明显低于B组(69.44%)(P<0.01);两组肾脏毒性无明显差异;两组白细胞下降发生率分别为26.47%和25.00%,无显著差异;血小板下降A组(52.94%)较B组(27.78%)显著(P<0.05)。结论:奈达铂治疗中晚期非小细胞肺癌的有效率不低于顺铂,胃肠道毒性显著减轻,且从临床的实用性和便利性上考虑,奈达铂更容易为临床医生和患者所接受。
Objective： To detect the efficacy and the side effect of the regimen for combined chemotherapy with Nedaplatin and cisplatin in the treatment of advanced non-small cell lung carcinoma. Methods： A total of 70 patients with advanced non-small cell lung carcinoma were divided into the Nedaplatin group （group A. n=34） and the traditional group （group B, n=36）. Results： The efficacy of group A was 32.35% and group B was 34.28%. There was no significant difference between the two groups in curative effect （P〉0.05）. A lower response rate of digestive reaction and nephrotoxicity （23.53%） occurred in group A. compared to that occurred in group B （69.44%）, with a significant difference between the two groups （P〈0.01）. There was no significant difference between two groups in the incidence of leukopenia （26.47%, 25.00%） and response rate of nephrotoxicity （2.94%, 11.11%）. There was a higher thromhocytopenia response rate （52.94%） in group A than in group B （27.78%）, with a significant difference between the groups （P〈0.05）. Conclusions： There is no significant difference between Nedaplatin and Cisplatin regimens and there is a lower digestive reaction and nephrotoxicity response rate than in Cisplatin group. Considering that it is clinical pragmatic and convenient, Nedaplatin is easy to be accepted by the patients and clinicans both.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第16期941-944,共4页
Chinese Journal of Clinical Oncology
关键词
奈达铂
顺铂
非小细胞肺癌
Nedaplatin cisplatin Non-small-cell lung Cancer （NSCLC）
